TME Pharma
TME Pharma is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. We specialize in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Our unique technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma’s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. Our clinical programs in glioblastoma and pancreatic cancer have delivered very promising results and further development is planned.
SNO 2023 poster: |
Press Release2024, July 22 08:00 a.m. TME Pharma announces strategic plan to externalize and monetize second clinical stage asset NOX-E36 2024, July 17 08:00 a.m. TME Pharma announces oral presentation of NOX-A12 GLORIA Phase 1/2 trial in glioblastoma at ESMO Congress 2024 2024, July 09 06:00 p.m. CEO Message H1 2024 |
EventsESMO Congress 2024
September 13 - 17 | Barcelona, Spain 24th Annual Biotech in Europe Forum
Aram Mangasarian, Ewelina Staniuk TIDES Europe
Aram Mangasarian, Stefan Vonhoff Latest Analyst ReportInvest Securities |